Tuesday, February 28, 2012

First Flight Venture Center graduates Envigen Pharmaceuticals

Former tenant, Envigen Pharmaceuticals, has graduated from the life science incubation program at First Flight Venture Center.

Envigen Pharmaceuticals, a research-based drug development company, became a tenant of First Flight in 2009, and have been designing and developing small drug-like molecules for their clients ever since.

Their goal is to develop a number of classes of new small drug-like molecules against life threatening diseases like cancer, HIV/AIDS and neurological disorders.

“The very first molecule we designed and synthesized was at First Flight,” explains Anil Sharma, President of Envigen.  “Like a pre-school, I learned all the business basics from the mentors at First Flight. It was a wonderful experience to work here.”

After three years, Envigen graduates as an economically viable company, with the background and know-how to run a successful business.

“We are thrilled to see our tenants graduate, and Anil is no exception,” exclaims First Flight President Andy Schwab. “We wish him continued success outside of First Flight.”

Life science companies similar to Envigen can benefit from First Flight’s entrepreneurial community and the mentors who reside on site. First Flight’s unique atmosphere provides start-ups a great place to grow and nurture their company.